Endologix Inc.

325 articles with Endologix Inc.

• Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States

  9/2/2020

  Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) (“Endologix” or the “Company”) today announced the first implant of its recently approved ALTO ® endograft outside of the United States, completed by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital, Auckland, New Zealand. "With the 7 mm infrarenal placement of its sealing ring, ALTO expands the endov

• Endologix Receives CE Mark for ALTO Abdominal Stent Graft System

  8/5/2020

  Transforming the treatment of aortic disorders, Endologix ® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced that it has received a CE Mark for the ALTO™ Abdominal Stent Graft System (ALTO). “We are very excited to receive a CE Mark for the ALTO system, that has been achieved through a strong partnership and collaboration with our European notified body, NSAI ” commented Matt Thompson, Chief Medical

• Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System & Official Start of U.S. Commercial Release

  7/30/2020

  Transforming the treatment of aortic disorders, Endologix ® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced the first commercial implant and the U.S. commercial release of its recently FDA-approved ALTO ® endograft for the treatment of abdominal aortic aneurysms (AAA). “ALTO represents a differentiation from traditional endovascular aneurysm repair (EVAR) and, with its introduction, a significant la

•  Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

  7/6/2020

  Files consensual plan of reorganization that would reduce approximately $180 million in debt and provide an approximately $30 million in additional exit financing

• Endologix Announces Departure of CFO and Appointment of Interim CFO

  6/18/2020

  Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO), will be departing the Company effective July 1, 2020 to become CFO of a private global healthcare company.

• Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

  6/15/2020

  Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer leaks.

• Endologix Reports First Quarter 2020 Financial Results

  5/11/2020

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced its financial results for the first quarter ended March 31, 2020.

• Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

  5/11/2020

  Endologix® Inc., a developer and marketer of innovative treatments for aortic disorders, announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System.

• Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

  5/1/2020

  Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after the market close on Monday, May 11, 2020.

• Endologix Appoints Tim A. Benner as Chief Commercial Officer

  4/14/2020

  Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John Zehren as the Company’s Chief Commercial Officer, effective as of April 14, 2020.

• Endologix Announces Preliminary Financial Results for First Quarter 2020

  4/6/2020

  Endologix, Inc. today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately $28.5 million.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 30, 2020

  3/30/2020

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to two newly hired employees.

• Endologix Adds Jane E. Kiernan to its Board of Directors

  3/17/2020

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced that it has appointed Jane E. Kiernan to its board of directors, effective March 12, 2020.

• Endologix Receives FDA Approval for Alto Abdominal Stent Graft System

  3/16/2020

  Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™ Abdominal Stent Graft System (Alto).

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 6, 2020

  3/6/2020

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of an inducement equity award to a newly hired employee.

• Endologix Announces Debt Restructuring Addressing 2020 Maturities

  2/24/2020

  Feb. 24, 2020 13:55 UTC IRVINE, Calif.--( BUSINESS WIRE )-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the “Existing Notes”), pursuant to which these investors exchanged an aggregate of approximately $11.0 million of the Existing Notes plus accrued inte

• Endologix Reports Fourth Quarter and Fiscal Year 2019 Financial Results

  2/19/2020

  Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019.

• Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference

  2/18/2020

  Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. ET on Wednesday, February 26, 2020 in New York, NY.

• Endologix Announces Preliminary Financial Results and Conference Call for Fourth Quarter and Full-Year 2019

  2/6/2020

  Feb. 6, 2020 13:30 UTC IRVINE, Calif.--( BUSINESS WIRE )-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2019 is expected to be approximately $35.8 million. Revenue for the full year ended December 31, 2019 is expected to be approximately $143.4 million.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb. 3, 2020

  2/3/2020

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of an inducement equity award to a newly hired employee.